Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'
| Errataetall: |
CommentOn: Ann Rheum Dis. 2021 Oct;80(10):1306-1311. - PMID 33762264 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 80(2021), 10 vom: 28. Okt., Seite e158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salviani, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 16.09.2021 Date Revised 04.12.2021 published: Print-Electronic CommentOn: Ann Rheum Dis. 2021 Oct;80(10):1306-1311. - PMID 33762264 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2021-220496 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325985650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325985650 | ||
| 003 | DE-627 | ||
| 005 | 20231225193617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2021-220496 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM325985650 | ||
| 035 | |a (NLM)34049854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salviani, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort' |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Rheum Dis. 2021 Oct;80(10):1306-1311. - PMID 33762264 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a B-lymphocytes | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Scolari, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Alberici, Federico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 80(2021), 10 vom: 28. Okt., Seite e158 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2021 |g number:10 |g day:28 |g month:10 |g pages:e158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2021-220496 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2021 |e 10 |b 28 |c 10 |h e158 | ||